kamada.com - רווח לפני ניכוי ריבית, מסים, בלאי ופחת KMDA

Kamada Ltd. enjoys global recognition in the therapy of orphan diseases, as confirmed by its current EBITDA. The value of 43.31 defines the current level of this metric. Growth is driven by the sale of plasma products and a contract with Takeda. Stability is ensured by a strict raw material transportation protocol utilizing specialized carriers, which eliminates disruptions in the supply of finished medications.

Kamada Ltd. (KMDA) maintains a monopoly status in the plasmapheresis segment, and the high cost of orphan drugs ensures a stable inflow of liquidity. An analysis of cash operating profit before deductions allows for an assessment of the daily volume of actual funds from core operations excluding depreciation and taxes, confirming the business's fundamental stability and its ability to generate free cash flow.